| Date Filed | Type | Description |
| 10/11/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 10/06/2023 |
4
| Butchko Julia G. (Chief Development Officer) has filed a Form 4 on Immunovant, Inc.|
Txns:
| Sold 296 shares
@ $35.54, valued at
$10.5k
Sold 1,439 shares
@ $36.39, valued at
$52.4k
|
|
| 10/06/2023 |
4
| Salzmann Peter (CEO) has filed a Form 4 on Immunovant, Inc.|
Txns:
| Sold 894 shares
@ $35.54, valued at
$31.8k
Sold 4,345 shares
@ $36.39, valued at
$158.1k
|
|
| 10/04/2023 |
SC 13D/A
| Roivant Sciences Ltd. reports a 55.3% stake in Immunovant, Inc. |
| 10/04/2023 |
4
| Roivant Sciences Ltd. (10% Owner) has filed a Form 4 on Immunovant, Inc.|
Txns:
| Granted 4,473,684 shares
@ $38, valued at
$170M
Bought 1,526,316 shares
@ $38, valued at
$58M
|
|
| 09/29/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 09/28/2023 |
8-K
| Quarterly results |
| 09/28/2023 |
FWP
| Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses: |
| 09/26/2023 |
FWP
| Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses: |
| 09/26/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 08/25/2023 |
4
| Levine Mark S. (Chief Legal Officer) has filed a Form 4 on Immunovant, Inc.|
Txns:
| Sold 12,285 shares
@ $20.3, valued at
$249.4k
Sold 1 shares
@ $20.89, valued at
$20.9 |
|
| 08/25/2023 |
4
| Barnett Eva Renee (CFO) has filed a Form 4 on Immunovant, Inc.|
Txns:
| Sold 14,385 shares
@ $20.3, valued at
$292k
Sold 1 shares
@ $20.89, valued at
$20.9 |
|
| 08/25/2023 |
4
| Butchko Julia G. (Chief Development Officer) has filed a Form 4 on Immunovant, Inc.|
Txns:
| Sold 12,332 shares
@ $20.3, valued at
$250.3k
Sold 1 shares
@ $20.89, valued at
$20.9 |
|
| 08/25/2023 |
4
| Macias William L. (Chief Medical Officer) has filed a Form 4 on Immunovant, Inc.|
Txns:
| Sold 12,332 shares
@ $20.3, valued at
$250.3k
Sold 1 shares
@ $20.89, valued at
$20.9 |
|
| 08/23/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 08/16/2023 |
4
| Salzmann Peter (CEO) has filed a Form 4 on Immunovant, Inc.|
Txns:
| Sold 91,744 shares
@ $21.34, valued at
$2M
Sold 11,314 shares
@ $22.04, valued at
$249.4k
|
|
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results |
| 08/08/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/27/2023 |
4
| Levine Mark S. (Chief Legal Officer) has filed a Form 4 on Immunovant, Inc.|
Txns:
| Sold 3,917 shares
@ $21.63, valued at
$84.7k
|
|
| 07/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/20/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/13/2023 |
4
| Salzmann Peter (CEO) has filed a Form 4 on Immunovant, Inc.|
Txns:
| Sold 3,233 shares
@ $19.73, valued at
$63.8k
|
|
| 07/13/2023 |
4
| Butchko Julia G. (Chief Development Officer) has filed a Form 4 on Immunovant, Inc.|
Txns:
| Sold 1,470 shares
@ $19.73, valued at
$29k
|
|
| 04/26/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/26/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/19/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/19/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
| 04/19/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/19/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/19/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/14/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/14/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 04/14/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
|